Bupa's purpose is helping people live longer, healthier, happier lives. With no shareholders, our customers are our focus. We reinvest profits into providing more and better healthcare for the benefit of current and future customers. Health insurance is at the core of our business globally. In some markets we also operate clinics, dental centres, hospitals, care homes and villages; giving us greater insight into how health systems work and enabling us to better meet the needs of our customers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

ENVERIC BIOSCIENCES ANNOUNCES REVERSE STOCK SPLIT

Enveric Biosciences | July 15, 2022

news image

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split will become effective at 4:05 p.m., New York time, on Thursday, July 14, 2022. Enveric’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “E...

Read More

Industrial Impact, Medical

PHARMING ANNOUNCES THE FIRST COMMERCIAL SHIPMENTS OF JOENJA® (LENIOLISIB) TO PATIENTS IN THE U.S.

Prnewswire | April 11, 2023

news image

Pharming Group N.V. announces the first commercial shipments of Joenja® to patients in the United States. Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the U.S. for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare and progressive primary immunodeficiency, in adult and pediatric patients 12 years of age and older. Under the terms of Pharming's 2019 exclusive license agreement with Novartis...

Read More

MedTech

EVAXION BIOTECH IDENTIFIES GONORRHEA AS SECOND BACTERIAL PRODUCT TARGET

Evaxion Biotech | July 04, 2022

news image

The clinical-stage biotechnology company Evaxion Biotech A/S which specializes in the creation of AI-driven immunotherapies, said today that it has chosen gonorrhea as its second bacterial target for the Company's EVX-B2 vaccine product candidate. Evaxion has opted to create a preventative vaccination against Gonorrhea, a sexually transmitted disease (STD) that has fast acquired antibiotic resistance, as its second bacterial target. Based on preliminary results in pre-clinical...

Read More

MedTech, Industry Outlook

IPA'S SUBSIDIARY, BIOSTRAND, SOLVES THE INFORMATION INTEGRATION DILEMMA (IID) FOR SYSTEMS BIOLOGY

Businesswire | May 31, 2023

news image

ImmunoPrecise Antibodies Ltd. an AI-driven biotherapeutic research and technology company, announced that its subsidiary, BioStrand®, has successfully solved the Information Integration Dilemma (IID) by developing a unique technology design that enables their patented HYFT Technology to encapsulate and unify diverse data modalities - including syntactical (sequence) data, 3D structural data, unstructured scientific information (e.g. scientific literature), and beyond - into a singular,...

Read More
news image

MedTech

ENVERIC BIOSCIENCES ANNOUNCES REVERSE STOCK SPLIT

Enveric Biosciences | July 15, 2022

Enveric Biosciences, Inc. a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split will become effective at 4:05 p.m., New York time, on Thursday, July 14, 2022. Enveric’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “E...

Read More
news image

Industrial Impact, Medical

PHARMING ANNOUNCES THE FIRST COMMERCIAL SHIPMENTS OF JOENJA® (LENIOLISIB) TO PATIENTS IN THE U.S.

Prnewswire | April 11, 2023

Pharming Group N.V. announces the first commercial shipments of Joenja® to patients in the United States. Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the U.S. for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare and progressive primary immunodeficiency, in adult and pediatric patients 12 years of age and older. Under the terms of Pharming's 2019 exclusive license agreement with Novartis...

Read More
news image

MedTech

EVAXION BIOTECH IDENTIFIES GONORRHEA AS SECOND BACTERIAL PRODUCT TARGET

Evaxion Biotech | July 04, 2022

The clinical-stage biotechnology company Evaxion Biotech A/S which specializes in the creation of AI-driven immunotherapies, said today that it has chosen gonorrhea as its second bacterial target for the Company's EVX-B2 vaccine product candidate. Evaxion has opted to create a preventative vaccination against Gonorrhea, a sexually transmitted disease (STD) that has fast acquired antibiotic resistance, as its second bacterial target. Based on preliminary results in pre-clinical...

Read More
news image

MedTech, Industry Outlook

IPA'S SUBSIDIARY, BIOSTRAND, SOLVES THE INFORMATION INTEGRATION DILEMMA (IID) FOR SYSTEMS BIOLOGY

Businesswire | May 31, 2023

ImmunoPrecise Antibodies Ltd. an AI-driven biotherapeutic research and technology company, announced that its subsidiary, BioStrand®, has successfully solved the Information Integration Dilemma (IID) by developing a unique technology design that enables their patented HYFT Technology to encapsulate and unify diverse data modalities - including syntactical (sequence) data, 3D structural data, unstructured scientific information (e.g. scientific literature), and beyond - into a singular,...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us